YOLFTbeta
30

Hubei Goto Biopharm Co.Ltd.

300966 · SHE · Healthcare / Biotechnology

23.80CNY-1.14 (-4.57%)

Price History

Full chart

Market Stats

Previous Close24.94
Open24.91
Day Range23.60 – 25.15
52-Week Range18.41 – 32.53
Volume1.73M
Market Cap2.96B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.83
Dividend Yield0.18%
Beta0.60
50-Day Avg24.54
200-Day Avg23.79

About

Hubei Goto Biopharm Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other materials. The company was formerly known as Hubei Goto Biopharm Co.,Ltd. and changed its name to Hubei Goto Biopharm Group Co., Ltd. in June 2026. Hubei Goto Biopharm Group Co., Ltd. was founded in 2006 and is based in Xiangyang, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Zubin Xi
  • Employees893
  • HeadquartersBuilding 1, Global Financial City, Xiangyang, China, 441057, China
  • Websitehttps://www.gotopharm.com

Leadership

  • Mr. Zubin XiChairman of the Board, GM and Research & Development Director · b. 1970
  • Mr. Xiangdong LiuCFO, Head of Accounting Agency & Non-Independent Director · b. 1974
  • Mr. Minglei LiNon Independent Director & Deputy GM · b. 1977
  • Ms. Wenjing ChenBoard Secretary & Deputy GM · b. 1973

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue333.69M437.30M464.80M468.12M590.89M604.57M566.40M536.60M606.18M
Growth (%)-+31.05%+6.29%+0.71%+26.23%+2.32%-6.31%-5.26%+12.97%
Cost of Revenue232.01M309.01M336.01M362.21M446.63M466.77M450.29M435.71M522.68M
Gross Profit101.68M128.30M128.79M105.90M144.26M137.81M116.11M100.89M83.50M
Gross Margin30.47%29.34%27.71%22.62%24.41%22.79%20.50%18.80%13.77%
Operating Expense46.47M49.96M49.09M48.60M81.55M98.90M96.58M143.31M117.08M
Operating Income55.21M78.33M79.69M57.30M62.71M38.90M19.53M-42.42M-33.58M
Operating Margin16.55%17.91%17.15%12.24%10.61%6.43%3.45%-7.91%-5.54%
EBITDA84.52M119.51M123.19M88.65M115.39M77.38M59.14M22.17M57.93M
EBITDA Margin25.33%27.33%26.50%18.94%19.53%12.80%10.44%4.13%9.56%
Net Income47.44M70.68M73.00M53.29M78.33M40.21M23.01M-27.59M-73.36M
Net Income Margin14.22%16.16%15.70%11.38%13.26%6.65%4.06%-5.14%-12.10%
R&D23.46M27.10M26.06M21.60M37.12M45.15M38.10M51.08M69.85M
R&D as % of Total Revenue7.03%6.20%5.61%4.62%6.28%7.47%6.73%9.52%11.52%
Interest Expense19.26M23.97M23.34M7.23M6.99M14.56M13.55M24.73M47.73M
Interest Expense % of Total Revenue5.77%5.48%5.02%1.54%1.18%2.41%2.39%4.61%7.87%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets483.34M615.08M817.68M804.43M1.21B2.07B2.45B2.79B2.85B
Total Liabilities182.88M206.82M336.43M264.58M382.83M1.09B1.42B1.78B1.94B
Total Equity300.45M408.26M481.25M534.54M807.05M928.07M952.75M923.14M826.22M
Cash44.07M65.11M129.66M28.96M209.91M438.42M181.97M141.18M85.85M
Total Debt55.95M80.90M147.32M139.77M161.54M770.30M763.01M1.11B-
Net Debt11.88M15.78M17.66M110.80M-48.37M331.88M581.03M965.76M1.12B

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-22.06M-47.89M8.50M13.47M58.00M-24.04M68.13M-20.59M41.04M
Investing Cash Flow-34.90M1.63M-33.07M-18.52M-105.41M-456.30M-402.35M-294.34M-
Financing Cash Flow57.70M50.72M71.73M-30.44M207.00M713.30M15.59M319.40M-
Capital Expenditure19.67M13.91M33.27M18.57M90.88M407.94M409.25M311.61M166.33M
Free Cash Flow-41.73M-61.80M-24.77M-5.09M-32.87M-431.98M-341.12M-332.20M-125.29M
Dividends Paid3.31M4.62M9.26M9.16M7.58M15.68M6.09M25.69M29.83M
FCF to OCF189.17%129.04%-291.30%-37.79%-56.67%1797.15%-500.67%1613.54%-305.31%
Dividend Paid to FCF-7.92%-7.48%-37.41%-179.97%-23.05%-3.63%-1.79%-7.73%-23.81%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------
EPS Actual0.220.110.210.110.110.110.000.030.120.050.000.03-0.08-0.08-0.120.01-0.11-0.18-0.360.03-0.32
Surprise---------------------
Timing---------------------

Key Statistics & Ratios

Market Cap2.96B
Enterprise Value4.31B
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.56
Price / Book3.86
EPS-0.83
Book Value6.96
Revenue (TTM)650.05M
Gross Profit (TTM)63.42M
EBITDA68.98M
Profit Margin-14.62%
Operating Margin-10.66%
Return on Equity-11.28%
Return on Assets-1.35%
Shares Outstanding115.28M
Shares Float56.47M
Beta0.60
Dividend Yield0.18%
Dividend Rate0.05
Payout Ratio0.00%

Dividends

20261×
0.04Jul 16, 2026
20241×
0.02Jun 12, 2024
20221×
0.14May 31, 2022